Andrew J. Aguirre
安德鲁·阿吉雷
MD, PhD
Associate Professor of Medicine; Co-Director, Pancreatic Cancer Research Program医学副教授；胰腺癌研究项目联合主任
👥Biography 个人简介
Andrew J. Aguirre, MD, PhD is a physician-scientist at Dana-Farber Cancer Institute whose laboratory focuses on the molecular underpinnings of pancreatic ductal adenocarcinoma (PDAC), with particular emphasis on oncogenic KRAS signaling and the mechanisms of resistance to KRAS-targeted therapies. He has led landmark CRISPR-based functional genomic screens in PDAC that identified synthetic lethal interactions and novel drug targets. His translational work bridges bench discoveries with early-phase clinical trials for patients with advanced pancreatic cancer, making him a central figure in the emerging era of RAS-directed therapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
KRAS G12C/G12D Inhibitor Development
Pioneered preclinical and translational studies evaluating direct KRAS inhibitors in PDAC models, characterizing adaptive resistance mechanisms including KRAS amplification and bypass signaling, and informing rational combination strategies tested in phase I/II trials.
CRISPR Functional Genomics in PDAC
Led large-scale CRISPR loss-of-function screens in pancreatic cancer cell lines to systematically identify context-specific dependencies, uncovering targetable vulnerabilities that could not be detected by genomic sequencing alone.
Precision Oncology Clinical Trials
Served as principal investigator for multiple investigator-initiated trials integrating molecular profiling with matched targeted therapies in advanced PDAC, demonstrating the feasibility and potential clinical benefit of biomarker-driven treatment selection.
Representative Works 代表性著作
Oncogenic KRAS Supports Pancreatic Cancer through Regulation of Nucleotide Synthesis
Nature Communications (2022)
Demonstrated that mutant KRAS rewires nucleotide metabolism in PDAC, identifying a metabolic vulnerability amenable to pharmacological targeting.
Functional Genomic Landscape of Oncogenic RAS Signaling Contexts
Cell (2023)
Genome-wide CRISPR screen characterizing differential genetic dependencies across KRAS mutation subtypes in pancreatic and other KRAS-driven cancers.
KRAS G12D Inhibition in Pancreatic Cancer: Preclinical Resistance Mechanisms
Cancer Discovery (2024)
Systematic analysis of acquired resistance to MRTX1133 and related KRAS G12D inhibitors, proposing combination regimens to forestall resistance.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 安德鲁·阿吉雷 的研究动态
Follow Andrew J. Aguirre's research updates
留下邮箱，当我们发布与 Andrew J. Aguirre（Dana-Farber Cancer Institute, Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment